Return to homepagePandemic Pact

Development of prognostic measures and possible treatments based on severe COVID-19 cases

Grant number: RITA2 / 126

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2022

  • Known Financial Commitments (USD)

    $202,233.34

  • Funder

    Estonian Research Council

  • Principal Investigator

    Unspecified Joel Starkopf

  • Research Location

    Estonia

  • Lead Research Institution

    University of Tartu, Department of Medical Sciences, Institute of Clinical Medicine

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

In this project, we describe the treatment results of COVID-19 patients hospitalized in Estonia in 2020 and identify the risk factors for poorer disease costs. We evaluate the variability of the applied treatment methods in Estonia and the compliance with the treatment standards. We analyze the immune response of COVID-19 patients both during hospital stay and in a later period, and try to explain the temporal dynamics of the development and persistence of the immune response in the Estonian cohort. Genetic studies help to clarify the inherited risk factors for COVID-19 in the Estonian population. We investigate the efficacy of plasma of COVID-19 survivors in the treatment of COVID-19 patients. The project represents the competence of the University of Tartu in clinical medicine, epidemiology and statistics, immunology, virology and genetics in cooperation with all Estonian hospitals where COVID-19 patients were treated.